title: Different vimentin expression in two clones derived from a human colocarcinoma cell line (LoVo) showing different sensitivity to doxorubicin.
abstract: We selected two clones, isolated from the human colocarcinoma cell line LoVo, showing a sensitivity to doxorubicin similar to (LoVo clone 5) or three times lower than (LoVo clone 7) the parental cell line. Since vimentin was atypically expressed in a human breast carcinoma cell line made resistant to doxorubicin, we looked at vimentin expression in these two clones with spontaneously different sensitivity to the drug. For comparison we used the parental cell line LoVo WT and LoVo/DX made resistant pharmacologically. mRNA for vimentin was undetectable by Northern blot analysis in LoVo WT and in LoVo clone 5, while expression of this gene was high in LoVo clone 7 and in LoVo/DX. This increase in mRNA levels was not related to an amplification of DNA, as suggested by Southern blot analysis. Immunofluorescence and immunocytochemistry findings confirmed, at protein level, the mRNA data. In LoVo clones 5 and 7, there were respectively 8.6% and 71% vimentin-positive cells, although the two clones showed similar expression of multidrug resistance gene 1 (mdr-1) and accumulated intracellular doxorubicin at similar levels. Similarly, drug efflux was the same for both clones. Our results show for the first time that cells resistant to doxorubicin express vimentin independently of the mdr glycoprotein. However when cells from clone 5 were transfected with human vimentin cDNA, they did not become resistant, indicating that vimentin can be considered as a marker of resistance in these cells but does not give rise to a resistant phenotype by itself.
authors.affiliation: Istituto di Ricerche Farmacologiche, Mario Negri, Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Conforti
authors.forename: A M
authors.initials: AM
authors.lastname: Codegoni
authors.forename: E
authors.initials: E
authors.lastname: Scanziani
authors.forename: E
authors.initials: E
authors.lastname: Dolfini
authors.forename: T
authors.initials: T
authors.lastname: Dasdia
authors.forename: M
authors.initials: M
authors.lastname: Calza
authors.forename: M
authors.initials: M
authors.lastname: Caniatti
authors.forename: M
authors.initials: M
authors.lastname: Broggini
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000502:physiology; D002999:Clone Cells / Q000737:chemistry; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000235:genetics; D004317:Doxorubicin / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D004354:Drug Screening Assays, Antitumor; D015870:Gene Expression; D006801:Humans; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014746:Vimentin / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004273:DNA, Neoplasm; D012333:RNA, Messenger; D014746:Vimentin; D004317:Doxorubicin